<DOC>
	<DOCNO>NCT02595970</DOCNO>
	<brief_summary>Evaluate psoriasis severity psychosocial impact use novel Patient Reported Outcome ( Simplified Psoriasis Index SPI ) 16 week , well long-term safety , tolerability efficacy secukinumab administer subcutaneously 52 week ( plus extension ) patient moderate severe psoriasis .</brief_summary>
	<brief_title>Study Evaluate Psoriasis Severity Its Psychosocial Impact Using Simplified Psoriasis Index ( SPI ) , Well Long-term Safety , Tolerability Efficacy Secukinumab Administered Subcutaneously Patients With Moderate Severe Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>patient history chronic , moderate severe plaque psoriasis ( PASI ≥12 ; BSA ( body surface area ) ≥10 IGA mod 2011 ( Investigator 's Global Assessment ) ≥3 ) least 6 month patient candidate systemic therapy . informed consent . previous treatment agent target IL17 ( interleukine17 ) IL17 receptor . recent treatment topical treatment ( 2 week ) , systemic agent ( 4 week methotrexate , Ciclosporine A ; systemic retinoids systemic treatment ) , TNF ( tumor necrosis factor ) inhibitor ( 3 month ) IL12/23 inhibitor ( 6 month ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Secukinumab</keyword>
	<keyword>Simplified Psoriasis Index</keyword>
	<keyword>CAIN457A</keyword>
	<keyword>AIN457AFR01</keyword>
	<keyword>AIN457A</keyword>
</DOC>